Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 14/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035690 | 1.00 | TSHR (0.50) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL584857 | 0.88 | TSHR (0.50) | TSHRKDM4EHTTTDP1KCNH2 | |
| Acetic Acid SCHEMBL30496778 | 0.82 | TSHR (0.46) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL9516253 | 0.82 | TSHR (0.48) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL9845018 | 0.82 | TSHR (0.48) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL1552204 | 0.82 | TSHR (0.48) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL31033436 | 0.81 | KCNH2 (0.50) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL4933865 | 0.81 | KCNH2 (0.55) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL17627703 | 0.81 | KCNH2 (0.55) | TSHRKDM4EHTTTDP1KCNH2 | |
| SCHEMBL1866120 | 0.81 | KCNH2 (0.55) | TSHRKDM4EHTTTDP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408407-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408407-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150237900-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORP (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150237900-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORP (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150237900-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | TAS2R5, TAS2R20, TAS2R10 | TSHR 2181/4885KDM4E 2256/4885HTT 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.